Improvement after a supplement is not the same as a comparative result
Start with the comparison. A before-and-after change alone cannot isolate the contribution of an ingredient.
Betaine
Selected research topic
Blood lipids
Some measured outcomes worsened in human comparison studies. The populations and conditions matter.
- Publications for this topic
- 2
- Human comparison publications
- 1
- Publications needing review
- 1
Findings in the studies
LDL cholesterol
- A worse result than the comparison group was reported.
What the comparison group used was not confirmed.
Single ingredientMeasurement and study conditions
- Study type
- Randomized controlled trial: subjects were randomly assigned to groups for comparison.
- Study population
- Human participants · Participant characteristics were not confirmed.
- Ingredients tested
- Single ingredient
- How results were compared
- Results were compared between groups.
- Measurement time
- Not confirmed.
Representative outcome and study details
Human studies reported between-group worsening in LDL cholesterol.
Single-ingredient studies · Human studies · Population not specified · between-group comparison
1 publications linked to this result
- Route, form, dose, or population details are incomplete, so the findings cannot be confirmed as directly comparable.
Data coverage and detailed study classifications
Paper counts are separated by research topic below. One paper may contribute to multiple findings.
Analysis status: Public-ready
Ingredient analysis date:
How the grade was determined: B
The 62.7 evidence score includes 3 independent human studies and 3 clinical studies in the representative benefit area. The B tier remains conservative because of the evidence centers on contextual or measured outcomes rather than general-use effects, limited repetition across independent human clinical studies.
The grade is based mainly on the research area with the most evidence. It does not mean the same result was found in other areas.
Papers linked to this ingredient overall: 60
Papers linked to this topic 2 · distinct papers 2 · papers with a confirmed human comparison 1 · papers needing additional review 1
A publication may appear in more than one count. These numbers should not be added. Ingredient-wide papers, topic-linked papers, and sources in outcome groups use different scopes. Adding source counts may count the same paper more than once.
- LDL cholesterol: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 1
What the research found
LDL cholesterol
The study reported worsening in this measurement.
Controlled study in people · Single ingredient · Unspecified population
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
Unspecified measured outcome
The study needs further checking before its result can be interpreted.
Meta-analysis · Single ingredient · Unspecified population
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
How to read research findings
How should I read research findings?
Research guidesNo clear difference and an uninterpretable result are different
A reported null comparison contains a result. An abstract without an interpretable comparison leaves a question unresolved.
Paper counts and study counts are different
Count original research separately from research that reanalyzes it. Publication volume is neither replication nor a quality rating.
Side effects and combination findings
Findings from this ingredient alone are shown separately from those involving another supplement or medication.
No reviewed caution rules are available yet. Reported caution findings are shown below.
Findings to review with care
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Side effects reported with this ingredient alone
Symptoms or adverse events reported in studies without another active ingredient.
ALT1 papers
Betaine at doses of 2–8 g/day for 12–24 weeks significantly reduced ALT and other liver injury markers in 70 participants with MASLD, with mild transient GI symptoms reported in ~35 %.Human studies · Randomized controlled trial